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Abstract
Background—Metabolic syndrome (MetS) refers to the clustering of cardio-metabolic risk
factors including dyslipidemia, central adiposity, hypertension and hyperglycemia in individuals.
Identification of pleiotropic genetic factors associated with MetS traits may shed light on key
pathways or mediators underlying MetS.
Methods and Results—Using the Metabochip array in 15,148 African Americans (AA) from
the PAGE Study, we identify susceptibility loci and investigate pleiotropy among genetic variants
using a subset-based meta-analysis method, ASsociation-analysis-based-on-subSETs (ASSET).
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Unlike conventional models which lack power when associations for MetS components are null or
have opposite effects, ASSET uses one-sided tests to detect positive and negative associations for
components separately and combines tests accounting for correlations among components. With
ASSET, we identify 27 SNPs in 1 glucose and 4 lipids loci (TCF7L2, LPL, APOA5, CETP, LPL,
APOC1/APOE/TOMM40) significantly associated with MetS components overall, all P< 2.5e-7,
the Bonferroni adjusted P-value. Three loci replicate in a Hispanic population, n=5172. A novel
AA-specific variant, rs12721054/APOC1, and rs10096633/LPL are associated with ≥3 MetS
components. We find additional evidence of pleiotropy for APOE, TOMM40, TCF7L2 and CETP
variants, many with opposing effects; e.g. the same rs7901695/TCF7L2 allele is associated with
increased odds of high glucose and decreased odds of central adiposity.
Conclusions—We highlight a method to increase power in large-scale genomic association
analyses, and report a novel variant associated with all MetS components in AA. We also identify
pleiotropic associations that may be clinically useful in patient risk profiling and for informing
translational research of potential gene targets and medications.
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Metabolic Syndrome (MetS) is the designation used for the clustering of cardio-metabolic
risk factors within an individual including dyslipidemia, central obesity, high blood pressure
and insulin resistance. Individuals with MetS are at increased risk of chronic diseases
including diabetes and cardiovascular disease, and all-cause mortality.1–4 Prevalence of
MetS varies by race and sex; in the US, it is higher in African American women than men,
and higher in Hispanics than in other race/ethnicity groups.5 Overall, the age-adjusted
prevalence ranges from 16–36% in the US and has been increasing in recent years,5 yet the
etiology of MetS is not well-understood. While insulin resistance, obesity, abnormal adipose
tissue metabolism and endothelial dysfunction are key contributors,6, 7 elucidation of the
precise MetS pathophysiology is complicated by the relatedness of these pathways and
potentially common underlying mediators. Investigation of genetic factors associated with
several MetS component traits may shed light on key pathways or mediators underlying the
syndrome as a whole, and also aid in genetic risk prediction of MetS.
As per the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP-
III) criteria,4, 8 MetS requires the presence of least three of the five following components:
central obesity, high blood pressure, elevated triglycerides, low high density lipoprotein
cholesterol (HDL), or fasting hyperglycemia; use of medication to treat the prior four
conditions also qualifies. The heritability of MetS, as defined above, is estimated to be
approximately 30%, although heritability of the individual components is generally higher
and may vary by ethnicity.9, 10 Genetic analyses of MetS are complicated by the inherently
heterogeneous definition of MetS. For example, the same three components may not cluster
in all MetS cases, and SNPs may be associated with one MetS component and not with
another. This complexity has prompted the use of novel methods such as factor analysis or
gene network analysis to better characterize the genetic architecture of MetS. Applying a
recently described method, ASsociation analysis based on subSETs (ASSET),11 we sought
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to identify MetS susceptibility loci in African Americans and investigate whether the
identified genetic variants show evidence of pleiotropy (i.e. a genetic variant influencing
multiple traits), and thus may explain some of the correlated architecture of MetS traits.
Using the Metabochip genotyping array12 in African Americans from the Population
Architecture using Genomics and Epidemiology (PAGE) Study, we contrast SNP
association findings from ASSET with those from a) logistic regression modeling MetS as a
binary outcome, and b) meta-analysis of the 5 individual components of MetS, coded as
binary variables. Unlike the traditional meta-analysis which may lack power when
associations for each of the components are heterogeneous (i.e. null, or have effects in
opposite directions), ASSET uses one-sided tests to detect positive and negative results for
the components separately and combines the tests taking into account correlations among
the components, and correction for these multiple tests. Significant results from ASSET are
tested in an independent Hispanic population.
Methods
Study Population
The study population includes 15,148 African American (AA) adults from the
Atherosclerosis Risk in Communities (ARIC) and Women’s Health Initiative (WHI) who
are part of the Population Architecture using Genomics and Epidemiology (PAGE) Study.13
Briefly, the ARIC study is a population-based cohort of non-Hispanic white and AA men
and women who were between 45–64 years of age in 1987-89 and recruited from four U.S.
communities: Forsyth County, North Carolina; Jackson, Mississippi; suburban areas of
Minneapolis, Minnesota; and Washington County, Maryland.14 A subset of the ARIC
cohort, n= 3,340 ARIC AA with available Metabochip genotyping were included in these
analyses. The WHI is a study of the etiology and prevention of chronic diseases in 161,838
postmenopausal women aged 50–79 years at recruitment (1993-98) from 40 clinical centers
in the US.15, 16 WHI consists of an observational study, two clinical trials of
postmenopausal hormone therapy (estrogen alone or estrogen plus progestin), a calcium and
vitamin D supplement trial, and a dietary modification trial. A subset of the baseline WHI
cohort, n=11,808 AA women with Metabochip genotyping data or imputed genotypes were
included in these analyses. The independent validation population includes 5172 self-
reported Hispanic/Latina women from the WHI that were genotyped on the Metabochip as a
part of the PAGE Study. All study protocols were approved by Institutional Review Boards
at the participating institutions, and all included participants gave informed consent.
Outcomes
MetS was defined in men and women according to the American Heart Association/National
Heart Lung and Blood Institute modified NCEP-ATP-III guidelines requiring the presence
of ≥ 3 of the following : waist circumference > 102cm in men or 88 cm in women;
triglyceride levels ≥ 150 mg/dl or treatment for dyslipidemia; HDL levels < 40 mg/dl in men
or <50mg/dL in women or treatment for dyslipidemia; blood pressure levels ≥ 130/85
mmHg or treatment for hypertension; and fasting plasma glucose levels ≥ 100 mg/dL or
treatment for diabetes.8, 17 Practically, these guidelines differ from the NCEP-ATP-III
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guidelines for the elevated fasting glucose criterion; the threshold is reduced from 110 to
100 mg/dL, which corresponds to the recently modified American Diabetes Association
criteria for impaired fasting glucose.18 MetS controls had ≤ 2 components. Only individuals
having non-missing data for the majority of components (three of five) at baseline were
included as MetS cases or controls in analyses; for example, an individual having three of
five components but missing data for the other two, was included as a MetS case, and an
individual not meeting criteria for three of the five components, even if the other two were
missing, was included as a control. In both ARIC and WHI, blood lipids and glucose were
measured in fasting samples. Using a tape measure, waist circumference was measured at
the level of the natural waist in a horizontal plane to the nearest 0.5cm. Resting blood
pressure was measured using standard protocols. Baseline medication use was assessed
using a combination of self-report and a medication inventory in ARIC and WHI. For
analyses involving MetS components, binary variables were created using the above criteria
to reflect either the presence or absence of the condition in individuals with non-missing
data for that component. The ASSET methodology, as described below, includes any
participant with baseline data for at least one of the five MetS components.
Genotyping
The Metabochip is a high density genotyping array designed for fine-mapping GWAS-
identified regions for cardio-metabolic and anthropometric traits (including genes previously
associated with blood lipids and glucose, waist circumference, and blood pressure), and also
includes genetic variants to capture ancestral diversity.12 Our analysis includes all
polymorphic SNPs with minor allele frequency ≥ 0.001 and passing stringent quality control
(QC) (n=169,196 SNPs). Genotyping QC procedures have been described previously,19 but
briefly, the following SNP QC criteria were applied: GenomeStudio GenTrain Score ≥0.6
and cluster separation score ≥0.4, call rate ≥ 0.95, replicate errors≤2, HapMap discordance ≤
1/30, and exact Hardy Weinberg equilibrium p ≥ 1e-6. The following sample criteria were
applied: sample call rate ≥ 0.95; no excessive heterozygosity (|F| > .35); no over-relatedness
(≤ 100 1st and 2nd degree relatives); sample not an ancestry outlier (≤ 6 standard deviations
in 1st 10 PCA); and among estimated 1st degree relative pairs, the 1st degree relatives with
lower call rates were dropped. A proportion of the WHI AA samples (54%) had high quality
imputed genotype data that were included in these analyses. QC methods for the imputation
are described in Liu et al. 20
Analysis
SNPs were coded using additive genetic models (0/1/2). Logistic regression was used to test
for study-specific associations between a) SNPs and MetS as a binary outcome, and b) SNPs
and individual MetS components coded as binary variables based on the modified NCEP-
ATP-III guidelines. All models were adjusted for age, sex (except WHI) and global ancestry
using principal components. Determination of ancestry principal components (PCs) was
performed with EIGENSOFT21, 22 as described in Buyske et al. (supplemental methods).19
In both ARIC and WHI, models were adjusted for the first two ancestry PCs. For each trait,
the results between ARIC and WHI were combined using a fixed effect meta-analysis using
inverse-variance weighting (no notable heterogeneity was observed). We then combined the
results for the five traits in ASSET (http://www.bioconductor.org/packages/devel/bioc/html/
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ASSET.html) using R software.23 ASSET uses a fixed effect meta-analysis on an adaptively
selected combination of the traits. As a comparison of the ASSET results, we performed
straightforward fixed effect meta-analysis between the five traits. In the discovery phase to
identify MetS susceptibility loci using either the binary MetS outcome or the ASSET
method, significance was defined as P<2e-7 (i.e. 0.05/169,196 SNPs tested). For
investigation of pleiotropy for SNPs that were significant in the ASSET models, i.e. looking
at SNP associations for the individual components, we used a nominal significance threshold
for each component, P<0.05.
ASSET
Proposed by Bhattacharjee et al., ASSET11 is a suite of statistical tools designed for pooling
association signals across multiple traits (or studies) when true effects may exist only in a
subset of the traits and could be in opposite directions. The method explores all possible
subsets of traits and evaluates fixed-effect meta-analysis-type test-statistics for each subset.
The final test-statistic is obtained by maximizing the subset-specific test-statistics over all
possible subsets and then evaluating its significance after efficient adjustment for multiple-
testing, taking into account the correlation between test-statistics across different subsets due
to overlapping participants (since multiple phenotypes may be available on participants).
The method not only returns a p-value for the overall evidence of association of a SNP
across traits, but also outputs the "best subset" containing the traits that contributed to the
overall association signal. The resulting test is much more powerful than considering all
combinations of traits and using a Bonferroni correction. For detection of association signals
with effects in opposite directions, ASSET allows subset searches separately for positively-
and negatively- associated traits and then combines association signals from two directions
using a chi-square test-statistic.
Validation
For the validation of significant SNPs in the Hispanic population, we used a nominal
threshold of significance, P<0.05.
Results
Overall, 15,148 AA were included in the ASSET analysis; these individuals had Metabochip
genotype data and baseline data for at least one MetS component. A subset of those
individuals, n=12,574, had sufficient non-missing data for the classification of 5,507 MetS
cases (43.7%) and 7,067 controls (56.2%). In both ARIC and WHI, the triglycerides
component was most frequently missing, with 4% and 24% missing, respectively. Among
those who could be classified, 38% of ARIC participants met MetS criteria, and 46% of
WHI women had MetS (Table 1). In ARIC, MetS cases were more likely to be female than
controls. In both ARIC and WHI, the high triglycerides component was the least prevalent
component in MetS cases, and also was rare (~5%) in controls.
Discovery
A total of 27 SNPs were significant (P<2e-7) in the 2-sided ASSET models (Table 2). Given
that many SNPs in each Metabochip locus are in high LD with each other and not
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independent, we restrict further discussion to the most significant SNPs, i.e. ‘top SNPs’, in
each locus and to other significant SNPs that are in low LD (r2<0.2 in AA) with these top
SNPs for a total of 11 SNPs in 5 loci. Only one SNP was significant in the logistic
regression analysis (rs10096633/LPL) or in the meta-analysis of MetS components
(rs12721054/APOC1). As indicated in Table 2, these two SNPs were also significant in the
ASSET analysis.
Pleiotropy
Of the top ASSET SNPs: rs12721054/APOC1 was associated with all five MetS
components; rs10096633/LPL was associated with glucose, triglycerides and HDL;
rs3135506/APOA5 was associated with triglycerides and HDL; rs7901695/TCF7L2 was
associated with waist circumference and glucose; and rs247616/CETP, rs7412/APOE and
rs61679753/TOMM40 were associated with waist circumference and HDL (Table 3).
Several top SNPs in CETP were significantly associated with only the HDL component in
ASSET: rs7205692, rs247619, rs6499862, and rs7499892. Pleiotropy results for other
significant SNPs are shown in Table 3. As an illustration of the ASSET method, results for
rs247616 from the ASSET, logistic regression model of MetS, and the meta-analysis of
MetS components are plotted in Figure 1.
Validation
We investigated MetS traits associations for the 27 SNPs significant in the AA ASSET
models in a large, independent population of Hispanic Americans, n=5172. Characteristics
of the population are presented in Supplementary Table 1. Of the 5172 Hispanic women,
3734 had sufficient data to be classified into MetS cases (42.6%) and controls (57.4%). In
contrast to AA cases in which high triglycerides was the least prevalent component, in
Hispanic cases, high glucose was the least prevalent component, at 60%. Of the 27 SNPs, 17
SNPs from three loci (LPL, APOA5, and CETP) were significant in the Hispanic population
at P<0.05 (Table 3). (Note: these loci also replicated at a more stringent threshold of
P=0.05/#of loci.) Pleiotropy was less evident in the Hispanic population, though overall,
trends were consistent with AA. None of the SNPs in the APOC1 or TCF7L2 loci were
significant in Hispanics, although the TCF7L2 SNPs were modestly associated with the
waist circumference component.
Discussion
While the clinical utility of MetS is a subject of ongoing debate,25 MetS is a highly
prevalent condition, and its prevalence is expected to increase along with the growing
obesity epidemic.5 Some propose that obesity is a critical precursor of MetS8, 26, yet
interestingly, MetS is also present among normal-weight individuals (at a prevalence of
approximately 5% in NHANES III)27, which may suggest that genetic factors unrelated to
obesity also play a role in MetS development.28 Indeed, the majority of MetS genes
identified in previous studies are from lipid metabolism pathways,29–31 though glucose30, 31
and blood pressure pathways30 are also implicated. Our study is consistent with these
findings; we identified variants in lipid genes (LPL, CETP, and APOA5) and in the
transcription factor 7-like 2 gene (TCF7L2). TCF7L2 variants are associated with increased
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risk of type 2 diabetes (T2D), including the intronic SNP that we identified (rs7903146)
which was recently reported in African Americans.32 For these SNPs, we also describe
additional associations with other MetS traits. Importantly, we report novel associations with
multiple MetS traits for rs12721054/APOC1, which may be African-specific, and
rs61679753/TOMM40. The validation of many of the associations in Hispanics, with the
exception of the putative African-specific SNPs, is supportive of the veracity our findings,
especially given that the Hispanic sample has a distinct genetic background from the AA
population.
Although family studies suggest that undetected genetic loci may contribute to the clustering
of MetS components, candidate gene and GWA studies of MetS have had variable success
in identifying reproducible, common genetic mechanisms underlying MetS. Instead, these
studies have generally identified genes from specific pathways which may be strongly
associated with 1 or 2 of the MetS components, but not necessarily 3 or more.29, 30
Similarly, most factor analysis and principal component (PC) studies have identified several
factors associated with MetS rather than a single common factor.9 In a PC analysis of MetS
and related (inflammation and thrombosis) domains using the IBC-chip genotyping
platform, Avery et al. identified variants in the diverse genes (APOC1, BRAP, and PLCG1)
associated with multiple domains in European-descent individuals.33 Specifically,
rs4420638/APOC1 was associated with elevated plasma glucose, atherogenic dyslipidemia,
vascular inflammation, and central obesity. These APOC1 results are consistent with our
findings, although our nearby APOC1 variant, rs12721054, was associated with all 5 MetS
components in AA, and is only modestly correlated with rs4420638, r2=0.39 in AA.
(rs4420683 failed our SNP QC so we are unable to assess its association in AA)
Interestingly, rs12721054 is potentially a novel African-descent variant. It is essentially
monomorphic in HapMap-3 CEU and rare in other HapMap-3 populations, e.g. minor allele
frequency=1% in HapMap-3 Mexicans. It was recently reported to be associated with
triglycerides in an AA GWAS of lipid traits.34 We found two additional significant SNPs in
this gene-rich region: a missense variant in APOE, rs7412, and rs61679753, an intronic
variant in TOMM40; both variants were associated with the HDL and waist circumference
components and are correlated in AA, though neither is in high LD with rs12721054/
APOC1 in AA (Supplemental Figure 1). Another variant associated with multiple MetS
components in the literature is an intronic SNP in the glucokinase regulatory protein
(GCKR) gene. The rs780094-T allele has been previously associated with increased
triglyceride levels and lower glucose levels in European-descent populations.35, 36 Although
GCKR SNPs did not reach our stringent threshold for statistical significance, we also found
strong inverse associations in AA for triglyceride and glucose components and additionally,
the waist circumference component for rs780094 (ASSET P-value= 7.4e-6) and for the
nearby GCKR variants: rs780093/intron (ASSET P-value=8.3e-6) and rs1260326/missense
(ASSET P-value=7.1e-7). In our study, rs780094 was also weakly associated with a fourth
component, HDL levels (Supplemental Figure 2). With component effects in opposite
directions and one decidedly null component, rs780094 provides another interesting
example of the utility of an approach such as ASSET to illustrate relationships between the
MetS components.
Carty et al. Page 7






















Overall, many of our top SNPs have been reported in GWAS of lipids traits
(rs10096633/LPL37, rs247616/CETP 38, rs7412/APOE 39, rs7499892/CETP 40) or T2D
(rs7901695/TCF7L2) 41 in mainly European-descent populations. The CETP association
with MetS has been implicated previously.42 We additionally identified several SNPs with
evidence of pleiotropic effects on MetS components. In addition to the APOC1 variant
associated with all components, variants in APOE, TOMM40, and CETP were associated
with HDL and waist circumference components, often with effects in opposite directions so
that the same allele was associated with increased risk of having one component (i.e. low
HDL) and decreased risk of having another component (i.e. high waist circumference).
TCF7L2, an important locus for diabetes, was associated with waist circumference and
glucose components in opposing directions, which may make it difficult to detect in the
context of MetS. LPL variants were associated with increased odds of having the
triglycerides, HDL and glucose components. In contrast to the ASSET findings, only one
LPL SNP was significantly associated with MetS in the logistic regression analysis.
While we have mentioned limitations of the conventional approaches, the ASSET method
also has limitations. It clusters associations into three categories: positive, null and negative
associations. For some SNP-trait associations, this categorization may be arbitrary and not
scientifically meaningful, i.e. if no trait has a null association. In cases with no heterogeneity
of effects, ASSET may perform similarly to a conventional meta-analysis, but with an
additional multiple testing penalty. Additionally, the two-sided ASSET test only provides a
P-value and not an overall effect size.
Our use of the Metabochip array has some advantages; namely, we capture and finely map
many of the known cardio-metabolic and anthropometric genetic variants identified to date
and genotype them on a common platform across studies using a centralized, stringent QC
process. However, our ability to identify novel MetS variants or pathways (in gene regions
not previously associated with cardio-metabolic traits in GWAS) is limited. One challenge
of the MetS outcome is that it requires non-missing data for several variables measured at
the same time point. For example, only 83% of our total sample had sufficient data for the
MetS analysis. An advantage of ASSET is that it can be used in samples with missing data
to give population level associations with MetS components, though it is important to
emphasize that in this case, these inferences may not be shared among individuals in the
population, i.e. ecological fallacy.43 In other words, while a SNP may be associated with 3
or more components in an ASSET analysis, it should not be inferred that accordingly, the
SNP is also associated with MetS in individuals. Also, ASSET may yield significant results
in the absence of pleiotropy, such as we saw for rs3764261/CETP or identify antagonistic
pleiotropy associations inconsistent with clinical MetS, i.e. the TCFL2 variants. We
acknowledge that common underlying cardio-metabolic mediators may contribute to the
observed pleiotropy; SNP effects on multiple traits may not be independent. (For more
discussion of mediated pleiotropy see review by Solovieff.44) An additional limitation
impacts our pleiotropy inferences; namely, the potential misclassification error inherent in
the MetS definition. For example, a user of lipid-lowering medication due to LDL
dyslipidemia would automatically be classified as having at least two MetS components
(HDL and triglycerides) even if he/she had normal HDL and triglyceride levels. Consistent
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with ATP III criteria in which the presence of T2D does not preclude a diagnosis of MetS,8
type 2 diabetics were not excluded from analyses, and account for <10% of the total sample.
But, similarly, a treated diabetic (and therefore classified as having the glucose component)
will likely have more aggressive treatment for cardiovascular disease prevention, such as use
of dyslipidemia medication, even if his/her lipid values are not particularly high, which
could create a spurious pleiotropic relationship between glucose, HDL, and triglycerides.
Although two LPL variants were associated with these three components, we do not see
strong evidence of this scenario in our results; lipids medication use (and potential
misclassification) was low at baseline in the WHI and ARIC AA populations, approximately
7% and 1% respectively.45 More generally, dichotomization of continuous traits into binary
components in this analysis also could result in loss of power and misclassification, although
we expect this misclassification error to be non-differential with respect to genotype and any
potential bias to be towards the null.
In summary, our discovery and validation results support previous genetic findings
emphasizing the importance of lipids traits for MetS. Of the 27 significant variants, 24 were
associated with the low HDL component in AA. With the exception of the potentially AA-
specific APOC1 variant which was associated with all MetS components, we did not find
strong evidence of a single underlying heritable factor for MetS clustering. This result is
consistent with other studies suggesting that a complex genetic architecture underlies MetS.9
However, we did identify a number of pleiotropic variants in AA, many demonstrating
antagonistic pleiotropy for cardio-metabolic traits important for MetS. We also report SNP
associations for these important cardiometabolic traits in a population with a high burden of
MetS, Hispanics, though pleiotropy findings in the Hispanic population were attenuated,
perhaps due to reduced power in the smaller sample. However, if confirmed, such
information on pleiotropy, and particularly, alleles with opposing effects, may be clinically
important, as it could inform translational research of potential gene targets and be useful in
risk profiling and in the development, marketing and prediction of side effects of new
medications.46 Additionally, we highlight the value of using new methods to increase power
and efficiency in large scale genomic association analyses, and demonstrate challenges
related to the use of the MetS construct in large-scale genomic studies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Plot of ASSET top SNP (rs247616) contrasting results from different methods Results from
ASSET, logistic regression models of MetS and MetS individual components, and the meta-
analysis of MetS components for rs247616-G are plotted. Note: P-values for MetS
components already include correction for multiple testing. The rs247616-G allele is
strongly associated with higher odds of low HDL levels, OR=1.35 (95%CI: 1.27–1.43;
P=3e-21), modestly associated with reduced odds of high waist circumference, OR=0.93
(95%CI: 0.88–0.98; P=0.031) and not associated with other MetS components (P>0.05). The
ASSET test takes these component effects in opposite directions into account (hence the low
P-value=1.2e-20). In contrast, results from the logistic regression analysis of MetS
(P=0.026) and the meta-analysis of MetS components (P=0.028) are attenuated due to null
component effects and effects in opposite directions.
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